Trial Profile
A retrospective study of Pazopanib for metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2018
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2018 New trial record
- 01 Jan 2018 Results (Data cut off 4 April 2017) assessing safety and efficacy published in the Anticancer Research